Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer

医学 前列腺癌 内科学 阉割 肿瘤科 前列腺 泌尿科 癌症 激素
作者
Kim N.,Andrew J. Armstrong,Bernd J. Krause,Ken Herrmann,Kambiz Rahbar,Johann S. de Bono,Nabil Adra,Rohan Garje,Jeff M. Michalski,Mette Moe Kempel,Karim Fizazi,Michael J. Morris,Oliver Sartor,Marcia A. Brackman,Michelle DeSilvio,Celine Wilke,Geoffrey Holder,Scott T. Tagawa
出处
期刊:European Urology [Elsevier BV]
卷期号:85 (4): 382-391 被引量:16
标识
DOI:10.1016/j.eururo.2023.12.004
摘要

Background and objective: [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) plus the standard of care (SoC) significantly improved overall survival and radiographic progression-free survival versus SoC alone in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer in the VISION trial. We evaluated the safety of additional cycles of 177Lu-PSMA-617 and the impact of longer observation time for patients receiving 177Lu-PSMA-617 plus SoC. Methods: VISION was an international, open-label study. Patients were randomised 2:1 to receive 177Lu-PSMA-617 plus SoC or SoC alone. The incidence of treatment-emergent adverse events (TEAEs) was assessed in prespecified subgroups of patients who received ≤4 cycles versus 5-6 cycles of treatment and during each cycle of treatment. The TEAE incidence was also adjusted for treatment exposure to calculate the incidence per 100 patient-treatment years of observation. This analysis was performed for the first occurrence of TEAEs. Key findings and limitations: The any-grade TEAE incidence was similar in cycles 1-4 and cycles 5-6. TEAE frequency was similar across all cycles of 177Lu-PSMA-617 treatment. No additional safety concerns were reported for patients who received >4 cycles. The exposure-adjusted safety analysis revealed that the overall TEAE incidence was similar between arms, but distinct trends for different TEAE types were noted and the incidence of events associated with 177Lu-PSMA-617 remained higher in the 177Lu-PSMA-617 arm. Conclusions and clinical implications: Longer exposure to 177Lu-PSMA-617 plus SoC was not associated with a higher toxicity risk, and the extended time for safety observation could account for the higher TEAE incidence in comparison to SoC alone. The findings support a favourable benefit-risk profile for 6 cycles of 177Lu-PSMA-617 in this setting and the use of up to 6 cycles of 177Lu-PSMA-617 in patients who are clinically benefiting from and tolerating this therapy. Patient summary: For patients with metastatic prostate cancer no longer responding to hormone therapy, an increase in the number of cycles of treatment with a radioactive compound called 177Lu-PSMA-617 from four to six had no additional adverse side effects.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
想要发文章完成签到 ,获得积分10
刚刚
华仔的应助被嘿嘿采纳,获得10
1秒前
liu完成签到,获得积分10
2秒前
momo完成签到 ,获得积分10
2秒前
jun发布了新的文献求助10
2秒前
molihuakai的应助被微笑采纳,获得10
2秒前
天真芷天发布了新的文献求助10
2秒前
符聪发布了新的文献求助10
3秒前
我是老大的应助被123采纳,获得10
4秒前
4秒前
5秒前
5秒前
周大福完成签到 ,获得积分10
5秒前
5秒前
锂离子完成签到,获得积分10
6秒前
所所的应助被nwds采纳,获得10
6秒前
爱笑白萱完成签到 ,获得积分10
7秒前
小张爱科研完成签到,获得积分10
7秒前
MOON完成签到,获得积分10
8秒前
jun完成签到,获得积分10
8秒前
8秒前
Li完成签到,获得积分10
8秒前
大个的应助被雍凡白采纳,获得10
8秒前
8秒前
Nicole发布了新的文献求助10
8秒前
帕尼尼同学完成签到,获得积分10
9秒前
celina完成签到,获得积分10
9秒前
传奇3的应助被王小冉采纳,获得10
9秒前
风吹麦浪的应助被李佳琪采纳,获得10
9秒前
刘谦发布了新的文献求助10
10秒前
YH完成签到,获得积分10
10秒前
10秒前
10秒前
符聪完成签到,获得积分10
10秒前
饭fan发布了新的文献求助10
10秒前
11秒前
忧虑的惜珊关注了科研通微信公众号
12秒前
12秒前
酒酿是也完成签到 ,获得积分10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186261
求助须知:如何正确求助?哪些是违规求助? 9574697
关于积分的说明 21837731
捐赠科研通 7783915
什么是DOI,文献DOI怎么找? 3434752
关于科研通互助平台的介绍 2559109
邀请新用户注册赠送积分活动 2481528